ZA201801432B - Anti¿lag¿3 antibodies - Google Patents

Anti¿lag¿3 antibodies

Info

Publication number
ZA201801432B
ZA201801432B ZA2018/01432A ZA201801432A ZA201801432B ZA 201801432 B ZA201801432 B ZA 201801432B ZA 2018/01432 A ZA2018/01432 A ZA 2018/01432A ZA 201801432 A ZA201801432 A ZA 201801432A ZA 201801432 B ZA201801432 B ZA 201801432B
Authority
ZA
South Africa
Prior art keywords
lag
antibodies
Prior art date
Application number
ZA2018/01432A
Other languages
English (en)
Inventor
Frederic Triebel
Chrystelle Brignone
Original Assignee
Immutep Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1515572.4A external-priority patent/GB201515572D0/en
Priority claimed from GBGB1612437.2A external-priority patent/GB201612437D0/en
Application filed by Immutep Sas filed Critical Immutep Sas
Publication of ZA201801432B publication Critical patent/ZA201801432B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA2018/01432A 2015-09-02 2018-03-01 Anti¿lag¿3 antibodies ZA201801432B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1515572.4A GB201515572D0 (en) 2015-09-02 2015-09-02 Anti-LAG-3 antibodies
GBGB1612437.2A GB201612437D0 (en) 2016-07-18 2016-07-18 Anti-lag-3 antibodies
PCT/EP2016/070664 WO2017037203A1 (en) 2015-09-02 2016-09-01 Anti-LAG-3 Antibodies

Publications (1)

Publication Number Publication Date
ZA201801432B true ZA201801432B (en) 2019-01-30

Family

ID=56852278

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/01432A ZA201801432B (en) 2015-09-02 2018-03-01 Anti¿lag¿3 antibodies

Country Status (19)

Country Link
US (2) US11680104B2 (enExample)
EP (2) EP3798234A1 (enExample)
JP (4) JP7074341B2 (enExample)
KR (2) KR102808640B1 (enExample)
CN (2) CN108699145A (enExample)
AU (2) AU2016316730B2 (enExample)
CA (1) CA2995639A1 (enExample)
DK (1) DK3344654T3 (enExample)
ES (1) ES2842306T3 (enExample)
IL (1) IL257798B2 (enExample)
MX (2) MX2018002610A (enExample)
MY (1) MY205096A (enExample)
PH (1) PH12018500369A1 (enExample)
PL (1) PL3344654T3 (enExample)
PT (1) PT3344654T (enExample)
RU (2) RU2021133819A (enExample)
SG (1) SG10201913864RA (enExample)
WO (1) WO2017037203A1 (enExample)
ZA (1) ZA201801432B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
MX2018002610A (es) * 2015-09-02 2018-09-27 Immutep Sas Anticuerpos anti-lag-3.
DK3356411T3 (da) 2015-10-02 2021-09-06 Hoffmann La Roche Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
KR102576042B1 (ko) 2016-10-11 2023-09-07 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
EP4201953A1 (en) 2017-04-03 2023-06-28 F. Hoffmann-La Roche AG Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
SG11201909154SA (en) 2017-04-05 2019-10-30 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3
KR102294136B1 (ko) * 2017-04-05 2021-08-26 에프. 호프만-라 로슈 아게 항-lag3 항체
SG11201909395TA (en) * 2017-04-27 2019-11-28 Tesaro Inc Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
CA3060984A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
KR102721137B1 (ko) 2017-05-30 2024-10-25 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
CA3073733A1 (en) * 2017-08-30 2019-03-07 Phanes Therapeutics, Inc. Anti-lag-3 antibodies and uses thereof
CA3085656A1 (en) * 2017-12-22 2019-06-27 Jiangsu Hengrui Medicine Co., Ltd. Lag-3 antibody pharmaceutical composition and use thereof
WO2019129137A1 (zh) * 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
US11661452B2 (en) 2018-03-20 2023-05-30 WuXi Biologics Ireland Limited Anti-lag-3 antibody polypeptide
WO2019186559A1 (en) * 2018-03-27 2019-10-03 Raz Yirmiya Microglia modulators for use in treatment of depression
CN110343178B (zh) * 2018-04-03 2022-07-22 上海开拓者生物医药有限公司 抗人lag-3单克隆抗体及其应用
US12060425B2 (en) * 2018-05-03 2024-08-13 Shanghai Epimab Biotherapeutics Co., Ltd. High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
CN110606892B (zh) * 2018-06-14 2023-09-26 华博生物医药技术（上海）有限公司 一种高亲和力高生物活性的lag-3抗体及其应用
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
CN111620949A (zh) * 2019-02-28 2020-09-04 三生国健药业（上海）股份有限公司 结合人lag-3的抗体、其制备方法和用途
GB201906127D0 (en) 2019-05-01 2019-06-12 Immutep S A Assays
GB201906118D0 (en) 2019-05-01 2019-06-12 Immutep S A Anti-LAG-3 binding molecules
AU2020276242B2 (en) 2019-05-13 2025-01-30 Regeneron Pharmaceuticals, Inc. Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer
EP3984554A4 (en) * 2019-06-11 2023-11-08 ONO Pharmaceutical Co., Ltd. IMMUNOSUPPRESSANT
KR20220164548A (ko) * 2020-04-03 2022-12-13 소렌토 쎄라퓨틱스, 인코포레이티드 Lag3에 결합하는 조작된 항체
CN115667304B (zh) * 2020-05-27 2026-04-17 安捷伦科技有限公司 抗人lag-3抗体及其在免疫组织化学(ihc)中的用途
CN116194480A (zh) 2020-08-13 2023-05-30 百时美施贵宝公司 将il-2重定向到目的靶细胞的方法
US20240101666A1 (en) 2020-10-23 2024-03-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
CN115819585B (zh) * 2020-12-10 2023-06-02 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
EP4680342A1 (en) 2023-03-13 2026-01-21 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
WO2025106736A2 (en) 2023-11-15 2025-05-22 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
WO2025128836A1 (en) * 2023-12-13 2025-06-19 Eli Lilly And Company Lag-3 agonist antibodies
WO2025242209A1 (zh) * 2024-05-24 2025-11-27 杭州阿诺生物医药科技有限公司 一种融合多肽及其用途
CN121620535A (zh) * 2024-05-27 2026-03-06 杭州阿诺生物医药科技有限公司 一种多功能融合蛋白
WO2026035866A1 (en) 2024-08-07 2026-02-12 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
DE69526377T2 (de) 1994-12-09 2002-11-07 Microscience Ltd Virulenzgene in der VGC2-Region von Salmonella
US5939045A (en) 1994-12-22 1999-08-17 Nissan Chemical Industries, Ltd. Organic bismuth derivatives for X-ray imaging
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DK0843557T3 (da) 1995-07-21 2003-03-10 Inst Nat Sante Rech Med Fremgangsmåder til detektion, identifikation, isolation og selektiv mærkning og målsøgning af Th1-lymfocytter ved hjælp af LAG-3 protein
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
CA2249998A1 (en) 1996-03-27 1997-10-02 Crc For Biopharmaceutical Research Pty. Ltd. The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
CA2305350C (en) 1997-09-23 2015-04-07 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof
JP2001525470A (ja) 1997-12-12 2001-12-11 マクロメド・インコーポレーテッド タンパク修飾のためのヘテロ官能化星形ポリ（エチレングリコール）
CN1204147C (zh) 1998-02-25 2005-06-01 利思进药品公司 提高以抗体为基础的融合蛋白的循环半衰期的方法
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US20060240024A1 (en) * 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
JP5010923B2 (ja) 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合蛋白質
ES2442386T3 (es) 2004-04-23 2014-02-11 Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
JP2008507555A (ja) 2004-07-22 2008-03-13 ジェネンテック・インコーポレーテッド シェーグレン症候群の治療方法
KR101318611B1 (ko) 2005-07-22 2013-11-13 교와 핫꼬 기린 가부시키가이샤 유전자 재조합 항체 조성물
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
US9244059B2 (en) * 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2009033161A1 (en) 2007-09-07 2009-03-12 The John Hopkins University Adenosine receptor agonists and antagonists to modulate t cell responses
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
IN2012DN00863A (enExample) 2009-07-31 2015-07-10 Medarex Inc
DK2462161T3 (en) 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN103249742B (zh) 2010-09-16 2017-04-12 巴利奥医药股份公司 抗人肿瘤坏死因子1型受体抗体
US9701749B2 (en) 2011-08-11 2017-07-11 Ono Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising PD-1 agonist
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US10280221B2 (en) * 2013-03-15 2019-05-07 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
MX2018002610A (es) * 2015-09-02 2018-09-27 Immutep Sas Anticuerpos anti-lag-3.

Also Published As

Publication number Publication date
IL257798A (en) 2018-06-28
PL3344654T3 (pl) 2021-05-17
WO2017037203A1 (en) 2017-03-09
US20190153112A1 (en) 2019-05-23
KR20180042412A (ko) 2018-04-25
JP2022137218A (ja) 2022-09-21
IL257798B2 (en) 2024-10-01
AU2023204589A1 (en) 2023-08-03
HK1256116A1 (en) 2019-09-13
DK3344654T3 (da) 2021-01-18
CN117510633A (zh) 2024-02-06
SG10201913864RA (en) 2020-03-30
MX2018002610A (es) 2018-09-27
ES2842306T3 (es) 2021-07-13
EP3798234A1 (en) 2021-03-31
JP7074341B2 (ja) 2022-05-24
MX2023001226A (es) 2023-03-03
NZ779096A (en) 2025-07-25
AU2016316730B2 (en) 2023-05-25
RU2760582C2 (ru) 2021-11-29
RU2021133819A (ru) 2021-12-10
CN108699145A (zh) 2018-10-23
BR112018004181A2 (en) 2018-09-25
JP2024116273A (ja) 2024-08-27
US20230272107A1 (en) 2023-08-31
EP3344654A1 (en) 2018-07-11
EP3344654B1 (en) 2020-10-21
KR20250073532A (ko) 2025-05-27
AU2016316730A1 (en) 2018-03-22
CA2995639A1 (en) 2017-03-09
PT3344654T (pt) 2021-01-26
PH12018500369A1 (en) 2018-09-03
RU2018111508A3 (enExample) 2020-02-18
JP2018537400A (ja) 2018-12-20
RU2018111508A (ru) 2019-10-04
KR102808640B1 (ko) 2025-05-14
US11680104B2 (en) 2023-06-20
IL257798B1 (en) 2024-06-01
MY205096A (en) 2024-10-01
JP2021097706A (ja) 2021-07-01
NZ740357A (en) 2025-05-30

Similar Documents

Publication Publication Date Title
ZA201801943B (en) Anti¿lag3 antibodies and uses thereof
ZA201800352B (en) Anti¿angptl8 antibodies and uses thereof
ZA201900373B (en) Anti-tim-3 antibodies
IL259048A (en) Antibodies against ror-1
SG10201601719RA (en) Anti-LAG-3 Antibodies
SG10201913864RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
IL253633B (en) Anti-transthyretin antibodies
GB201621439D0 (en) IL-11Ra Antibodies
GB201521393D0 (en) Antibodies
SG10202010735PA (en) Tau-binding antibodies
SG11201706126WA (en) Anti-transthyretin antibodies
GB201521382D0 (en) Antibodies
GB201610044D0 (en) Antibodies
GB201803296D0 (en) No details
IL255323A0 (en) Anti-fcrn antibodies
GB201616699D0 (en) Antibodies
ZA201808317B (en) Anti-tnfrsf25 antibodies
GB201603291D0 (en) Antibodies
PT3484921T (pt) Anticorpos anti-il-22r
SG11201610594WA (en) Anti-il4-il 13 bispecific antibodies
GB201503438D0 (en) Antibodies
GB201522394D0 (en) Antibodies
IL272676B (en) Bispecific antibodies against il-4 and il-13
IL284022B1 (en) Anti-transthyretin antibodies